GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.18
-0.10 (-1.37%)
▼
5d:
-5.77%
30d:
-11.47%
90d:
-6.63%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.16
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.65
32.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.18, which is considered oversold relative to its 30-day fair value range of $7.38 to $7.94. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.0) compared to its historical average (6.1). Remarkably, the market is currently pricing in an annual earnings decline of 6.8% over the next few years. This pessimistic expectation contrasts with the company's recent 43.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a strong downtrend. The price is currently testing key support at $7.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+51.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRFS is in a strong downtrend. The price is currently testing key support at $7.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+51.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.38 -
$7.94
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.3% below Wall St target ($10.87)
- CAUTION: 5-day price weakness (-5.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$7.38 -
$7.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.16
Resistance Level
$7.73
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.97
Wall Street Target
$10.87
(+51.3%)
Revenue Growth (YoY)
-4.8%
Earnings Growth (YoY)
43.5%
Profit Margin
5.6%
Valuation Discount vs History
-6.8% cheaper
PE vs Historical
5.0 vs 6.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.8%
(market-implied from PE analysis)
1-Year Target
$6.69
(-7%)
2-Year Target
$6.24
(-13%)
3-Year Target
$5.81
(-19%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$7.13
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 36.0%)
$79.19
(+1003%)
Base:
(SPY PE: 5.0, Growth: 36.0%)
$18.07
(+152%)
Bear:
(PE: 4.2, Growth: 36.0%)
$15.36
(+114%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 10.40 | Current EPS (TTM): $0.70
Bull Case
$16.02
(+123%)
Analyst growth 100.0%, PE expands to 11.4
Base Case
$14.56
(+103%)
Market implied 100.0%, PE stable at 10.4
Bear Case
$4.95
(-31%)
Severe decline -20.0%, PE contracts to 8.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.0 to 6.1
Stabilization Target:
$8.81
(+22.7%)
PE Expansion Potential:
+22.7%
Share & Embed Analysis
Last updated: June 24, 2026 12:30 AM ET
Data refreshes hourly during market hours. Next update: 1:30 AM
Data refreshes hourly during market hours. Next update: 1:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1219 | 52 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 56 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 66 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 64 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 63 BUY |
